Geron Corporation (0IV3.L)
0IV3.L Stock Price Chart
Explore Geron Corporation interactive price chart. Choose custom timeframes to analyze 0IV3.L price movements and trends.
0IV3.L Company Profile
Discover essential business fundamentals and corporate details for Geron Corporation (0IV3.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
229.00
Website
https://www.geron.comCEO
Dawn Carter Bir
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
0IV3.L Financial Timeline
Browse a chronological timeline of Geron Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 6 Nov 2025
Revenue estimate is $55.24M.
Earnings released on 6 Aug 2025
EPS came in at -$0.02 surpassing the estimated -$0.03 by +31.37%, while revenue for the quarter reached $49.04M , missing expectations by -11.19%.
Earnings released on 7 May 2025
EPS came in at -$0.03 surpassing the estimated -$0.04 by +16.99%, while revenue for the quarter reached $39.60M , missing expectations by -23.56%.
Earnings released on 26 Feb 2025
EPS came in at -$0.04 falling short of the estimated -$0.02 by -55.10%, while revenue for the quarter reached $47.54M , beating expectations by +4.97%.
Earnings released on 7 Nov 2024
EPS came in at -$0.04 surpassing the estimated -$0.08 by +52.34%, while revenue for the quarter reached $28.27M , missing expectations by -54.52%.
Earnings released on 8 Aug 2024
EPS came in at -$0.10 falling short of the estimated -$0.10 by -0.04%, while revenue for the quarter reached $882.00K , beating expectations by +155.80%.
Earnings released on 2 May 2024
EPS came in at -$0.09 surpassing the estimated -$0.10 by +4.11%, while revenue for the quarter reached $304.00K , beating expectations by +954.35%.
Earnings released on 28 Feb 2024
EPS came in at -$0.09 surpassing the estimated -$0.11 by +16.81%, while revenue for the quarter reached $23.00K , missing expectations by -71.78%.
Earnings released on 2 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.02%, while revenue for the quarter reached $164.00K , beating expectations by +177.97%.
Earnings released on 4 Aug 2023
EPS came in at -$0.09 falling short of the estimated -$0.08 by -7.94%, while revenue for the quarter reached $29.00K , missing expectations by -56.06%.
Earnings released on 11 May 2023
EPS came in at -$0.07 surpassing the estimated -$0.10 by +29.98%, while revenue for the quarter reached $21.00K , missing expectations by -70.00%.
Earnings released on 17 Mar 2023
EPS came in at -$0.10 surpassing the estimated -$0.12 by +15.30%, while revenue for the quarter reached $103.00K , missing expectations by -17.27%.
Earnings released on 29 Sept 2022
EPS came in at -$0.10 falling short of the estimated -$0.09 by -8.54%, while revenue for the quarter reached $297.00K , beating expectations by +240.73%.
Earnings released on 30 Jun 2022
EPS came in at -$0.07 surpassing the estimated -$0.09 by +25.94%, while revenue for the quarter reached $73.00K , missing expectations by -36.30%.
Earnings released on 31 Mar 2022
EPS came in at -$0.09 surpassing the estimated -$0.10 by +11.14%, while revenue for the quarter reached $123.00K , beating expectations by +20.29%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 31 Dec 2021
EPS came in at -$0.10 , while revenue for the quarter reached $1.04M .
Earnings released on 30 Sept 2021
EPS came in at -$0.08 surpassing the estimated -$0.08 by +3.38%, while revenue for the quarter reached $109.00K , beating expectations by +41.10%.
Earnings released on 30 Jun 2021
EPS came in at -$0.09 , while revenue for the quarter reached $107.00K .
Earnings released on 31 Mar 2021
EPS came in at -$0.09 , while revenue for the quarter reached $137.00K .
Earnings released on 31 Dec 2020
EPS came in at -$0.07 , while revenue for the quarter reached $50.00K .
Earnings released on 30 Sept 2020
EPS came in at -$0.06 , while revenue for the quarter reached $108.00K .
0IV3.L Stock Performance
Access detailed 0IV3.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.